Article info

Download PDFPDF
Prognostic Value of Human Epidermal Growth Factor Receptor 2 (Her-2)/neu in Patients With Advanced Ovarian Cancer Treated With Platinum/Paclitaxel as First-Line Chemotherapy: A Retrospective Evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany

Authors

  1. Address correspondence and reprint requests to Felix Hilpert, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Michaelisstrasse 16, 24105 Kiel, Germany. E-mail: fhilpert{at}email.uni-kiel.de.

Citation

Pfisterer J, Du Bois A, Bentz E, et al
Prognostic Value of Human Epidermal Growth Factor Receptor 2 (Her-2)/neu in Patients With Advanced Ovarian Cancer Treated With Platinum/Paclitaxel as First-Line Chemotherapy: A Retrospective Evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany

Publication history

  • First published January 1, 2009.
Online issue publication 
January 01, 2009

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.